Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder

Herrera-Guzmán, Ixchel; Gudayol-Ferré, Esteve; Mandujano, Jennifer Lira; Herrera-Abarca, Jorge E.; Herrera-Guzmán, Daniel; Montoya-Pérez, Karina Salud; Guàrdia‐Olmos, Joan

doi:10.1016/j.psychres.2007.04.012

Cited by 61 publications

(59 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with bupropion for 12 weeks improved measures of visual memory and mental processing speed in 20 patients with MDD. 32 A naturalistic study of outpatients with depression responding to at least 4 weeks of AD treatment found that those who received bupropion had similar scores as healthy subjects on a battery of neurocognitive tests, whereas those treated with SSRIs or venlafaxine did not. 37 Several studies with newer agents have been designed to include cognitive function as a primary or key secondary outcome.…”

Section: Effects Of Antidepressants On Cognitive Dysfunctionmentioning

confidence: 99%

Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment

et al. 2014

View full text Add to dashboard Cite

Major depressive disorder is a common condition with a high rate of recurrence, chronicity, and staggering economic burden, including disability in the workforce.1 In 2010, MDD was the second leading medical cause of burden globally, with highest estimates of disability in people of working age.2 In Canada, the annual prevalence of MDD is 3% to 4% overall, and 79% of people with MDD report some interference with work functioning, either decreased work productivity and (or) absenteeism.1 In addition to work impairment, the psychosocial impact of MDD often affects a person's level of functioning in family and social relationships. While there is clearly an association between improvement in depressive symptoms and functioning, symptom improvement can also be dissociated from functional improvement and work loss.3,4 Hence there has been increasing recognition that symptomatic remission is an insufficient goal of treatment for MDD and that return to premorbid psychosocial functioning should be targeted. 5Cognitive dysfunction refers to deficits in attention, verbal and nonverbal learning, short-term and working memory, visual and auditory processing, problem solving, processing speed, and motor functioning. Cognitive dysfunction may be a primary mediator of functional impairment in MDD. 6 Cognitive complaints are core symptoms of acute MDEs, and diminished ability to think or concentrate and (or) indecisiveness are criterion items for the diagnosis of MDD. Several other core symptoms of MDD may act as mediators of cognitive dysfunction, including psychomotor retardation, amotivation, fatigue, insomnia, and mood disturbances. Deficits on neuropsychological testing are well demonstrated in people with MDD, compared with healthy subjects, with many studies and meta-analyses showing moderate effect sizes in neurocognitive domains of processing speed, attention, executive function, learning, and memory 7,8 as well as in cognitive affective bias. Cognitive affective bias reflects distorted information processing and (or) focus moving away from positive stimuli and toward negative stimuli, 7 and abnormal responses to negative feedback and decision making. It is also apparent that, while cognitive dysfunction in MDD may improve with treatment and resolution of depressive symptoms, cognitive deficits can still be detected even in periods of symptom remission. In a 3-year, follow-up study of patients with MDD, the proportion of time with cognitive complaints was reported as 94% during acute depressive episodes; this remained at 44% despite full or partial symptom remission during treatment. 10 Cognitive performance on tests of immediate memory, attention, 11 and processing speed 12 was reported to be inferior in patients with MDD who met criteria for remission, compared with healthy subjects. Meta-analyses show that cognitive deficits in executive function are still present in remitted patients, 13,14 which may explain persistent psychosocial impairment in remission.While it is beyond the scope of our paper to review the unde...

show abstract

Section: Effects Of Antidepressants On Cognitive Dysfunctionmentioning

confidence: 99%

Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Current antidepressant therapies have limited capacity to alleviate the cognitive deficits in MDD (Biringer, 2005;Herrera-Guzman et al, 2009;Behnken et al, 2010;Spronk et al, 2011). There is some evidence that cognitive deficits in MDD patients are predictive of a failure to respond to SSRI/SNRI, suggesting that some cognitive aspects of MDD may define a subtype of patients who require additional therapeutic interventions (Dunkin et al, 2000;Gorlyn et al, 2008;Herrera-Guzman et al, 2008). Novel antidepressants that also enhance cognition, independently of their antidepressant activity, might offer a clear therapeutic advantage in these patients (Clark et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target

et al. 2013

View full text Add to dashboard Cite

“…2. Reported to improve cognitive dysfunction [42], fatigue, sleepiness, pleasure, interest, and energy [42,43•], and to be at least weight neutral [17].…”

Section: Discussionmentioning

confidence: 99%

The role of dopaminergic agents in improving quality of life in major depressive disorder

IsHak

Davis²,

Jeffrey³

et al. 2009

Curr Psychiatry Rep

View full text Add to dashboard Cite

Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.

show abstract

Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder

Cited by 61 publications

References 41 publications

Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment

Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target

The role of dopaminergic agents in improving quality of life in major depressive disorder

Contact Info

Product

Resources

About